Generating hepatic cell lineages from pluripotent stem cells for drug toxicity screening

Melissa A. Baxter, Cliff Rowe, Jane Alder, Sean Harrison, Karen Piper Hanley, B. Kevin Park, Neil R. Kitteringham, Chris E. Goldring, Neil Hanley

    Research output: Contribution to journalArticlepeer-review


    Hepatotoxicity is an enormous and increasing problem for the pharmaceutical industry. Early detection of problems during the drug discovery pathway is advantageous to minimize costs and improve patient safety. However, current cellular models are sub-optimal. This review addresses the potential use of pluripotent stem cells in the generation of hepatic cell lineages. It begins by highlighting the scale of the problem faced by the pharmaceutical industry, the precise nature of drug-induced liver injury and where in the drug discovery pathway the need for additional cell models arises. Current research is discussed, mainly for generating hepatocyte-like cells rather than other liver cell-types. In addition, an effort is made to identify where some of the major barriers remain in translating what is currently hypothesis-driven laboratory research into meaningful platform technologies for the pharmaceutical industry. © 2010 Elsevier B.V. All rights reserved.
    Original languageEnglish
    Pages (from-to)4-22
    Number of pages18
    JournalStem Cell Research
    Issue number1
    Publication statusPublished - Jul 2010


    Dive into the research topics of 'Generating hepatic cell lineages from pluripotent stem cells for drug toxicity screening'. Together they form a unique fingerprint.

    Cite this